Global Amnestic Disorders Therapeutics Market, By Disease Type (Anterograde, Retrograde, Transient Global, Infantile Amnesia), Drug Class (Cholinesterase Inhibitors, Memantine, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others) - Industry Trends and Forecast to 2030.
Amnestic Disorders Therapeutics Market Analysis and Size:
The increasing prevalence of amnestic disorders acts as one of the major factors driving the growth of the amnestic disorders therapeutics market. The advancements in medical technology and increasing healthcare infrastructure expenditure accelerate the amnestic disorders therapeutics market growth.
Data Bridge Market Research analyses that the global amnestic disorders therapeutics market which was USD 3,372 million in 2022, would rocket up to USD 6,521 million by 2030, and is expected to undergo a CAGR of 4.20 % during the forecast period. This indicates that the anterograde segment dominates the disease type segment of the amnestic disorders therapeutics market owing to the advancements in technology that have led to the development of advancements in drug products for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Amnestic Disorders Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021(Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Market By Disease Type (Anterograde, Retrograde, Transient Global, Infantile Amnesia), Drug Class (Cholinesterase Inhibitors, Memantine, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
It refers to the market for medications and treatment approaches used to manage and alleviate symptoms associated with amnestic disorders. Amnestic disorders are a group of neurological conditions characterized by impaired memory function and the inability to form new memories. These disorders can be caused by various factors, including brain injury, neurodegenerative diseases (such as Alzheimer's), stroke, or certain medications.
Global Amnestic Disorders Therapeutics Market Dynamics
Drivers
- Increasing Prevalence of Amnestic Disorders:
The rising incidence and prevalence of amnestic disorders, such as Alzheimer's disease, mild cognitive impairment (MCI), and other forms of dementia, are significant drivers for the therapeutics market. As the aging population continues to grow worldwide, the number of individuals affected by amnestic disorders is expected to increase, creating a higher demand for effective treatments.
- Growing Awareness and Diagnosis:
There has been a significant increase in public awareness and understanding of amnestic disorders, leading to improved diagnosis rates. Early detection and intervention are crucial for managing amnestic disorders, and as more individuals seek diagnosis and treatment, the demand for therapeutics rises.
- Advancements in Diagnostic Technologies:
Advances in diagnostic technologies, such as brain imaging techniques (MRI, PET scans), cerebrospinal fluid (CSF) biomarkers, and genetic testing, have improved the accuracy of diagnosing amnestic disorders. These advancements enable healthcare professionals to identify individuals at risk or in the early stages of the disease, driving the need for therapeutic interventions.
Opportunities
- Government Initiatives and Funding:
Governments and healthcare organizations across the globe are increasingly recognizing the social and economic burden of amnestic disorders. Consequently, they are initiating programs and allocating funds to support research, early diagnosis, and treatment of these disorders. Government support and funding drive the development of new therapeutics and promote market growth.
- Increasing Healthcare Expenditure:
Rising healthcare expenditure, both in developed and developing countries, plays a crucial role in the growth of the amnestic disorders therapeutics market. The increasing affordability of advanced therapies, improved healthcare infrastructure, and expanding insurance coverage contribute to higher access to treatment options for patients.
Restraints
- Limited Understanding of the Underlying Mechanisms:
The exact causes and mechanisms behind amnestic disorders, such as Alzheimer's, are not yet fully understood. This lack of knowledge can hinder the development of targeted therapies and limit the effectiveness of existing treatments.
Challenges
- Regulatory Challenges
The regulatory landscape for drug approval and market entry is stringent and complex. Meeting the rigorous standards set by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), can be challenging and time-consuming. Delays in regulatory approvals can slow down the availability of new treatments for amnestic disorders.
This global amnestic disorders therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global amnestic disorders therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO®, AJOVY®, UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business.
- In November 2022, A wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Sun Pharma Advanced Research Company Ltd.
Global Amnestic Disorders Therapeutics Market Scope
The global amnestic disorders therapeutics market is segmented on the basis of disease type, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Anterograde
- Retrograde
- Transient Global
- Infantile Amnesia
Drug Class
- Cholinesterase Inhibitors
- Memantine
- Others
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- online Pharmacies
- Others
Global Amnestic Disorders Therapeutics Market regional analysis/insights
The global amnestic disorders therapeutics market is analysed, and market size insights and trends are provided for type, mode of delivery, therapeutic indication, application and end-users, as referenced above.
The countries covered in the global amnestic disorders therapeutics market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
North America is expected to dominate the amnestic disorders therapeutics market due to the presence of major key players, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global amnestic disorders therapeutics market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for the global amnestic disorders therapeutics market, impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global amnestic disorders therapeutics market. The data is available for the historic period 2015-2020.
Competitive Landscape and Global Amnestic Disorders Therapeutics Market Share Analysis
The global amnestic disorders therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global amnestic disorders therapeutics market.
Some of the major players operating in the global amnestic disorders therapeutics market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Actelion Pharmaceuticals Ltd (Switzerland)
SKU-